Eysuvis is an FDA-approved prescription corticosteroid eye drop for short-term dry eye disease treatment in adults. Approved in 2020, it was the first corticosteroid cleared specifically for dry eye flares. It contains loteprednol etabonate at 0.25% with AMPPLIFY drug delivery technology.
Eysuvis blocks ocular surface inflammation as early as day 4 of treatment. The AMPPLIFY system uses nanoparticles below 500 nanometers to penetrate the eye’s mucus barrier. Restasis and Xiidra handle long-term maintenance while Eysuvis targets acute flares directly. Clinical trials show significant reduction in eye redness and discomfort versus placebo.
Patient reviews rate Eysuvis 9.5 out of 10 on Drugs.com with 100% positive responses from verified users. The drug is used for up to 2 weeks per course and is not intended for daily maintenance therapy. This review covers the ingredients, side effects, cost, and how Eysuvis compares to alternatives on the market.
What Are Eysuvis Eye Drops?
Eysuvis is an FDA-approved prescription corticosteroid eye drop formulated for the short-term treatment of dry eye disease symptoms in adults, approved in 2020 as the first corticosteroid cleared specifically for this condition. Manufactured by Kala Pharmaceuticals and now distributed by Alcon, it contains loteprednol etabonate at a 0.25% concentration. The formula uses proprietary AMPPLIFY drug delivery technology to penetrate the eye’s mucus barrier more effectively than conventional drops.
Here’s what makes it different from other eye drops. AMPPLIFY uses mucus-penetrating nanoparticles below 500 nanometers (0.5 micrometers) in size. These particles bypass the natural mucus layer on the eye’s surface. More medication reaches the inflamed tissue compared to standard ophthalmic formulations.
Treatment with Eysuvis lasts up to two weeks per course. The drop is not intended for daily maintenance use. Can patients use it long-term? No. Each course targets an acute flare, not the chronic underlying condition. Patients with recurring flares should discuss long-term management options with their eye doctor.
Is Eysuvis a Steroid?
Yes. Eysuvis contains loteprednol etabonate, classified as a ‘soft’ corticosteroid designed to minimize systemic absorption while reducing local ocular inflammation with a lower risk profile than traditional ophthalmic steroids. Loteprednol is metabolized quickly after working at the ocular surface. This reduces the risk of typical steroid complications during short courses.
The 0.25% concentration is lower than most corticosteroid eye drops on the market. Standard loteprednol formulations such as Lotemax use 0.5%. Does a lower concentration mean less effective? Not for dry eye flares. The reduced concentration targets the specific inflammation driving flare symptoms. Eye care specialists consider it a targeted, controlled-risk option for this specific condition.
What Is Eysuvis Used For?
Eysuvis is indicated for the short-term treatment of the signs and symptoms of dry eye disease in adults, including eye redness, burning, scratchy sensation, and blurred vision caused by ocular inflammation during disease flares. The FDA cleared this specific indication in 2020. No other corticosteroid eye drop held this exact dry eye disease approval before then.
Dry eye disease symptoms worsen during flares. A flare is a sudden worsening beyond a patient’s usual symptom baseline. Eysuvis targets the inflammation driving the flare directly. It is not intended for everyday use between episodes.
How Do Eysuvis Eye Drops Work?
Eysuvis works by blocking inflammation at the ocular surface, which is the primary driver of dry eye flare-ups and their associated symptoms including redness, burning sensation, and visual disturbance in affected adults. The corticosteroid component, loteprednol etabonate, suppresses the inflammatory response within the eye tissue. Reduced inflammation lowers swelling and irritation at the ocular surface.
To be clear, the AMPPLIFY technology is central to how Eysuvis delivers the medication. Mucus normally acts as a defensive barrier on the eye’s surface. Standard eye drops struggle to penetrate this barrier effectively. Eysuvis nanoparticles pass through the mucus layer. The result is greater drug concentration at the target tissue.
Here’s the step-by-step dosing process patients follow:
How to Use Eysuvis:
- Wash hands thoroughly before each use.
- Shake the bottle for 2 to 3 seconds before applying.
- Remove contact lenses before instilling the drops.
- Tilt head back and squeeze 1 to 2 drops into each affected eye.
- Wait 15 minutes before reinserting contact lenses.
- Repeat four times daily for up to 2 weeks as directed.
How Long Does Eysuvis Take to Work?
Eysuvis delivers measurable relief from dry eye discomfort as early as day 4 after starting treatment, based on clinical trial data from multiple randomized, vehicle-controlled studies conducted in patients with dry eye disease. Significant improvement in conjunctival hyperemia (ocular redness from inflamed blood vessels) was also documented at day 15. Treatment differences versus vehicle (placebo) drops were statistically significant across studies.
The full 2-week course maximizes therapeutic benefit. And here is the best part: some patients notice improvement within the first few days of use. Symptoms that do not improve within the first week warrant a clinical reassessment. Patients should contact their eye doctor if symptoms worsen during treatment rather than continuing independently.
What Are the Ingredients in Eysuvis?
Eysuvis contains loteprednol etabonate at 2.5 mg/mL (0.25%) as its sole active ingredient, suspended in a sterile ophthalmic formulation that uses Kala’s AMPPLIFY drug delivery system to penetrate the ocular mucus barrier more effectively. Each milliliter delivers a precise therapeutic dose of loteprednol to the ocular surface. The active component belongs to the corticosteroid drug class and has a molecular formula of C24H31ClO7 (molecular weight 467.0).
The inactive ingredients maintain suspension stability and tolerability. Eysuvis also contains the preservative benzalkonium chloride. Patients with known sensitivity to preservatives should discuss this ingredient with their prescribing doctor before starting.
Full Ingredient List:
- Loteprednol etabonate 2.5 mg/mL (active ingredient)
- Glycerin
- Sodium citrate dihydrate
- Sodium chloride
- Poloxamer 407
- Edetate disodium dihydrate
- Citric acid
- Water for injection
- Benzalkonium chloride (preservative)
The product is supplied in an 8.3 mL bottle within a 10 mL container (NDC 71571-333-83). Kala Pharmaceuticals originally manufactured it in Watertown, MA. Does the bottle require special storage? No. Room temperature conditions away from direct light are sufficient. The bottle must be shaken before every use to resuspend the nanoparticles properly.
What Are the Benefits of Eysuvis Eye Drops?
Eysuvis is the first and only FDA-approved corticosteroid developed specifically for the short-term treatment of dry eye disease flares, giving prescribers a validated rescue option distinct from all other corticosteroid eye drops on the market. This approval status reflects the largest clinical development program in dry eye history at the time of its 2020 approval. The indication specifically covers active flares in adults.
The fast onset is a defining advantage. Clinical data shows measurable relief as early as day 4. How does that compare to Restasis? Maintenance medications such as Restasis require months before full therapeutic effect. Speed of action makes Eysuvis uniquely suited for acute flare management where patients need relief quickly.
The AMPPLIFY technology delivers the drug at a lower concentration. Using 0.25% loteprednol rather than higher percentages reduces total steroid exposure. Lower exposure during the 2-week window supports a favorable tolerability profile. Clinical trials showed a low incidence of significant intraocular pressure (IOP) elevation relative to baseline.
Key Benefits of Eysuvis:
- First and only FDA-approved corticosteroid for dry eye disease
- Fast relief: measurable improvement as early as day 4
- AMPPLIFY technology for superior drug penetration
- Low 0.25% concentration reduces steroid exposure
- Compatible with other dry eye medications
- Targets inflammation at the source of flare symptoms
Does Eysuvis Reduce Inflammation?
Yes. Eysuvis significantly reduces conjunctival hyperemia, an objective clinical measure of ocular surface inflammation, compared to vehicle drops in multiple pooled randomized controlled trials involving patients with active dry eye disease. Conjunctival hyperemia refers to visible redness from dilated blood vessels on the eye surface. Treatment differences were statistically significant at day 15 compared to placebo.
Loteprednol suppresses the release of inflammatory mediators at the cellular level. The reason is simple: these proteins signal the immune response that drives redness and discomfort. Blocking their release lowers the total inflammatory burden on the eye’s surface. Patients experience both objective redness reduction and subjective discomfort relief as a result.
Can You Use Eysuvis With Other Eye Drops?
Yes. Eysuvis can be used alongside other dry eye medications, including artificial tears and long-term prescription drops such as Restasis, Cequa, or Xiidra, with a minimum 5-minute waiting period between different eye drop applications. The 5-minute interval prevents dilution of the active ingredient and potential drug interaction between formulations. Eye care specialists confirm this compatibility in standard dry eye management protocols.
During an active flare, Eysuvis is added temporarily to the patient’s existing regimen. The maintenance medications continue throughout the 2-week course. After the Eysuvis course ends, patients return to their baseline routine. Doctors may adjust long-term therapy if flares become frequent enough to require repeated rescue treatment.
What Do Eysuvis Reviews Say?
Eysuvis holds an average rating of 9.5 out of 10 from 8 verified patient reviews on Drugs.com, with 100% of reviewers reporting a positive treatment experience, making it one of the highest-rated prescription dry eye treatments on the platform. The small sample size reflects its prescription-only status and relatively recent 2020 approval. Is 8 reviews enough to trust? For a prescription-only drug with a narrow indication, this sample is meaningful. Broader loteprednol formulations average 7.3 out of 10 from 43 reviews across Drugs.com.
Eysuvis vs. Loteprednol Ratings Comparison:
| Drug | Avg. Rating | Reviews | Positive % |
|---|---|---|---|
| Eysuvis (loteprednol 0.25%) | 9.5 / 10 | 8 | 100% |
| Loteprednol ophthalmic (other) | 7.3 / 10 | 43 | 70% |
What Are the Positive Experiences With Eysuvis?
Eysuvis users consistently report rapid and dramatic relief from dry eye flares after failing multiple other treatments, with several patients describing it as the only drop to provide meaningful improvement after years of searching for a solution. One Drugs.com reviewer noted 6 weeks of sustained relief after two years of unmanaged dry eye disease. Another described noticeable improvement in blurry vision within 2 days of starting treatment.
In fact, several reviewers noted they actively recommended Eysuvis to others. One user suggested asking for Eysuvis before starting Restasis, describing it as a way to bridge the induction period. Another reviewer called it ‘gentle but effective’ compared to Xiidra, which they had stopped due to side effects. The consistent message is fast relief where other treatments had failed.
Patients with complex diagnoses also respond well. One reviewer with ocular rosacea and meibomian gland dysfunction (60% gland loss) reported near-complete elimination of lid wiper epitheliopathy at maximum dosing. The reviewer noted a slight IOP increase but described it as acceptable. The relief disappeared after tapering, highlighting both the drug’s effectiveness and its short-term nature.
What Are the Common Complaints About Eysuvis?
Eysuvis users most consistently cite the bottle design as a primary frustration, describing a dropper that releases drops too quickly when tipped into position, wasting expensive medication from a bottle that costs over $500 USD per fill. Multiple independent reviewers on Drugs.com and WebMD flagged this same issue. The drops can pour out before the patient is positioned correctly above the eye.
Cost is the second most common concern. At approximately $529.25 USD for an 8.3 mL bottle without insurance, affordability is a real barrier. No generic version exists. Some patients report difficulty accessing the manufacturer savings program or finding commercial insurance that covers the prescription.
One patient reported a severe allergic reaction that caused eyelid swelling within two days of first use. Symptom return after the 2-week course also frustrates users who expect longer-lasting results. Bottom line: Eysuvis works during the treatment window, but the effects are temporary by design.
How Does Eysuvis Compare to Alternatives?
Eysuvis occupies a fast-acting rescue therapy role in dry eye management that no long-term maintenance medication or over-the-counter artificial tear can replicate, given its FDA-approved anti-inflammatory mechanism and short-term onset of action. The comparison landscape includes other corticosteroids, immunomodulators, and non-preserved artificial tears. Each category addresses a different treatment goal at a different timeline.
Dry Eye Treatment Comparison:
| Treatment | Role | Duration | Mechanism |
|---|---|---|---|
| Eysuvis | Flare rescue | Up to 2 weeks | Corticosteroid (0.25%) |
| Restasis / Cequa | Long-term maintenance | Ongoing | Cyclosporine (immunomodulator) |
| Xiidra | Long-term maintenance | Ongoing | Lifitegrast (LFA-1 antagonist) |
| Artificial tears | Symptomatic lubrication | As needed | Lubricant (no anti-inflammatory) |
| Lotemax | Post-op / allergy inflammation | Short-term | Corticosteroid (0.5%) |
How Does Eysuvis Compare to Lotemax?
Eysuvis and Lotemax both contain loteprednol etabonate as the active ingredient but differ in FDA indication, concentration, and drug delivery technology, making them clinically distinct despite sharing the same therapeutic compound. Eysuvis at 0.25% is approved specifically for dry eye disease. Lotemax at 0.5% is approved for allergic conditions, eye infections, and post-surgical inflammation. The AMPPLIFY delivery system is exclusive to Eysuvis.
The price difference is significant. Eysuvis costs approximately $529.25 USD for 8.3 mL. Generic loteprednol ophthalmic ranges from $69.49 to $86.93 USD for 5 mL. Patients without a specific dry eye flare indication may find the generic loteprednol more accessible. The proprietary formulation in Eysuvis has no bioequivalent generic approved by the FDA.
How Does Eysuvis Compare to Restasis and Xiidra?
Eysuvis fills a fast-acting rescue role that Restasis and Xiidra cannot serve, as both maintenance medications require months of consistent daily use before reaching full therapeutic effect in dry eye disease patients. Restasis (cyclosporine 0.05%) and Cequa (cyclosporine 0.09%) modulate the immune response over weeks and months. Xiidra (lifitegrast 5%) also requires sustained use for maximum efficacy.
Here’s the thing: these treatments are not in competition. One Drugs.com reviewer explicitly recommended Eysuvis as a bridge therapy while starting Restasis. The reviewer noted Eysuvis delivers near-term relief during the induction phase when Restasis has not yet built up full effect. Eye care specialists describe combination use as clinically appropriate. Eysuvis and maintenance therapy serve different phases of dry eye management.
What Are the Side Effects of Eysuvis?
Eysuvis most commonly causes instillation site pain, reported in 5% of patients during 2-week clinical trials compared to 4% in the vehicle group, representing the only adverse reaction documented in 1% or more of users in the pivotal study data. The pain was described as mild to moderate in severity. No other treatment-related adverse reactions exceeded the 1% threshold in trial populations.
Less common side effects are shared with other corticosteroid eye drops as a class. Should patients worry about eye pressure? The prescribing information mandates a magnified eye examination before any prescription renewal to monitor this. Clinical trial data showed low incidence of significant IOP elevation versus baseline. The risk is manageable with proper medical oversight.
Eysuvis Side Effects Summary:
- Instillation site pain: 5% of patients (most common, mild to moderate)
- Intraocular pressure increase: low incidence in clinical trials
- Slowed wound healing: class effect, risk increases with longer use
- Corneal thinning or tearing: possible with prolonged corticosteroid exposure
- Susceptibility to eye infections: viral, bacterial, and fungal
- Cataract development or worsening: risk with extended use beyond 2 weeks
Are There Serious Side Effects From Eysuvis?
Yes. Eysuvis carries prescribing warnings for delayed wound healing, corneal thinning, increased intraocular pressure, and cataract development, all of which are class effects of corticosteroid eye drops that increase in likelihood with use beyond the approved 2-week course. The 2-week limit is the primary safeguard against these risks. Staying within the approved duration significantly limits exposure to serious adverse outcomes.
Viral infections are the most critical contraindication. Eysuvis must not be used by patients with active herpes simplex keratitis, vaccinia, varicella, or other viral corneal infections. Corticosteroids can worsen these infections and extend their course. Patients with a history of herpes simplex require close physician oversight and may need additional antiviral coverage.
One patient on Drugs.com reported a severe allergic reaction involving eyelid swelling after two days of use. Fungal infections of the cornea can also develop during corticosteroid treatment. Any persistent corneal ulceration during the treatment course warrants immediate medical evaluation and likely discontinuation.
Who Should Avoid Eysuvis?
Eysuvis is contraindicated in patients with active viral eye infections including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and any mycobacterial or fungal infections of the eye or ocular structures, per the FDA prescribing information. These contraindications are class effects of corticosteroids. Immune suppression from loteprednol can allow these infections to worsen or spread if left untreated under corticosteroid cover.
Patients with active corneal damage or ulceration should not use Eysuvis until the affected eye has fully healed. The medication slows wound healing at the ocular surface. Is allergy to the preservative a problem? Yes. Patients with known allergies to loteprednol or benzalkonium chloride require an alternative therapy without that component.
Patients Who Should Avoid Eysuvis:
- Active herpes simplex keratitis (any form)
- Active vaccinia or varicella eye infection
- Fungal or mycobacterial eye infections
- Unhealed corneal injury or active ulceration
- Known allergy to loteprednol or benzalkonium chloride
- Patients advised against any ophthalmic corticosteroid by their physician
Children, pregnant patients, and breastfeeding mothers fall into a special review category. The prescribing information covers pediatric use, pregnancy (category risk assessment), and lactation separately. No well-controlled human studies confirm safety during pregnancy. A thorough risk-benefit discussion with the prescriber is required before use in these populations.
How Much Does Eysuvis Cost?
Eysuvis costs approximately $529.25 USD per 8.3 mL bottle at full retail price, which equals roughly $63.77 per milliliter, making it one of the higher-priced prescription eye drops on the market for patients without insurance coverage or manufacturer assistance. A single bottle contains enough medication for one full 2-week treatment course at the standard dosing of 1 to 2 drops, 4 times daily, in both eyes.
No FDA-approved generic version of Eysuvis currently exists. The AMPPLIFY delivery technology is under patent protection, and loteprednol etabonate at 0.25% in this specific formulation has no bioequivalent generic. Can patients substitute with generic loteprednol? Technically yes, but generic loteprednol carries a different FDA indication and a higher 0.5% concentration. It is not a direct substitute for dry eye flare treatment.
Eysuvis Cost Breakdown:
| Detail | Value |
|---|---|
| Bottle size | 8.3 mL |
| Full retail price | ~$529.25 USD |
| Per mL cost | ~$63.77 USD |
| Generic available? | No |
| Manufacturer savings | Yes, via eysuvis.myalcon.com |
| Insurance coverage | Varies by plan; prior auth often required |
Alcon offers a savings program through the official Eysuvis website. Commercial insurance plans may cover Eysuvis with prior authorization. Medicare Part D coverage depends on the specific plan formulary. Patients are advised to check formulary status and apply for the copay card before filling the first prescription to avoid unexpected out-of-pocket costs.
Is Eysuvis Worth the Price?
Yes. Eysuvis delivers validated clinical benefit for patients in active dry eye flares who have not found adequate relief from artificial tears or slower-acting prescription maintenance medications, with a measurable onset of action within 4 days that no other approved option matches. For patients who respond well, the 2-week window of relief provides quality-of-life improvement that many describe as life-changing after years of failed treatments.
For patients without insurance coverage, the $529.25 USD price tag is a significant barrier. Is there any way to reduce the cost? Yes. The manufacturer savings program through eysuvis.myalcon.com provides copay assistance for eligible patients. Discussing savings program eligibility with both the prescriber and pharmacist before the first fill is strongly advisable.
Where Can You Buy Eysuvis?
Eysuvis is available only with a valid prescription from a licensed eye care provider and can be filled at major retail pharmacies, specialty ophthalmic pharmacies, and participating mail-order pharmacy services that accept standard prescription benefit plans. No over-the-counter version exists. A thorough eye examination is required before the prescription can be issued or renewed per the FDA prescribing guidelines.
Mail-order pharmacies often offer lower out-of-pocket costs for prescription fills. The manufacturer’s savings page lists participating pharmacy options and copay assistance details. Specialty pharmacies focused on ophthalmic medications may provide additional patient education support. Confirming formulary coverage before ordering prevents unexpected cost surprises at pickup.
Is Eysuvis Worth It?
Yes. Eysuvis is a clinically validated, FDA-approved corticosteroid eye drop that delivers fast-acting relief for dry eye disease flares, with 100% positive reviews from verified Drugs.com patients who used the medication as prescribed for up to 2 weeks. The AMPPLIFY technology improves drug delivery at a lower concentration than competing corticosteroid formulations. Its unique FDA indication for dry eye flares distinguishes it from all other ophthalmic steroids.
The bad news? Cost and bottle design are the main drawbacks. At $529.25 USD without insurance, affordability is a real constraint for many patients. The dropper design has drawn consistent criticism for wasting doses. These practical frustrations do not undermine the clinical efficacy, but they do affect the overall user experience.
Pay attention to this: Eysuvis works best as part of a complete dry eye management plan. Short answer: for flare relief, it is the most targeted option available by prescription. Patients experiencing acute dry eye flares who have exhausted over-the-counter options should discuss Eysuvis with their eye doctor as a validated first-line rescue therapy.